Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiske midler - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

laboratorios menarini s.a. - dexketoprofentrometamol - filmovertrukne tabletter - 12,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

laboratorios menarini s.a. - dexketoprofentrometamol - granulat til oral opløsning - 12,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

menarini international operation - dexketoprofentrometamol - filmovertrukne tabletter - 25 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

menarini international operation - dexketoprofentrometamol - granulat til oral opløsning - 12,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

menarini international operation - dexketoprofentrometamol - injektions-/infusionsvæske, opløsning - 50 mg/2ml (25 mg/ml)

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

menarini international operation - dexketoprofentrometamol, tramadolhydrochlorid - filmovertrukne tabletter - 75+25 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

menarini international operation - dexketoprofentrometamol, tramadolhydrochlorid - granulat til oral opløsning i brev - 75+25 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.